Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan/tadalafil FDC vs monotherapies in PAH
NCT03904693Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of macitentan + tadalafil in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Jul 2019; status: completed.
02
Drugs
macitentan + tadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03904693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904693.